Search Results - "Journal of cardiovascular pharmacology"
-
1
Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
Published in Journal of cardiovascular pharmacology (01-09-2016)“…BACKGROUND:Nonalcoholic fatty liver disease (NAFLD) is one of the most common hepatic diseases in the general adult population. Dyslipidemia, hyperuricemia,…”
Get full text
Journal Article -
2
G Protein-Coupled Receptor Signaling Through β-Arrestin-Dependent Mechanisms
Published in Journal of cardiovascular pharmacology (01-09-2017)“…β-arrestin1 (or arrestin2) and β-arrestin2 (or arrestin3) are ubiquitously expressed cytosolic adaptor proteins that were originally discovered for their…”
Get full text
Journal Article -
3
Exosomes From Adipose-derived Mesenchymal Stem Cells Protect the Myocardium Against Ischemia/Reperfusion Injury Through Wnt/β-Catenin Signaling Pathway
Published in Journal of cardiovascular pharmacology (01-10-2017)“…Mesenchymal stem cells (MSCs) and their secreted exosomes exert a cardioprotective role in jeopardized myocardium. However, the specific effects and underlying…”
Get full text
Journal Article -
4
Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II–III Systolic Heart Failure
Published in Journal of cardiovascular pharmacology (24-10-2020)“…The NLRP3 inflammasome has been implicated in the development and progression of heart failure. The aim of this study was to determine the safety of an oral…”
Get full text
Journal Article -
5
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
Published in Journal of cardiovascular pharmacology (01-07-2014)“…Pharmacological blockade of the mineralocorticoid receptor (MR) ameliorates end-organ damage in chronic heart failure. However, the clinical use of available…”
Get full text
Journal Article -
6
Role of Hypertension on the Severity of COVID-19: A Review
Published in Journal of cardiovascular pharmacology (01-11-2021)“…The novel coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly evolved into a global pandemic…”
Get full text
Journal Article -
7
The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse
Published in Journal of cardiovascular pharmacology (01-04-2019)“…BACKGROUND:Activation of the NLRP3 inflammasome is a primary driver of sterile inflammation in response to myocardial ischemia reperfusion. Pharmacologic…”
Get full text
Journal Article -
8
Irisin Protects Heart Against Ischemia-Reperfusion Injury Through a SOD2-Dependent Mitochondria Mechanism
Published in Journal of cardiovascular pharmacology (01-12-2018)“…Irisin, a muscle-origin protein derived from the extracellular domain of the fibronectin domain-containing 5 protein (FNDC5), has been shown to modulate…”
Get full text
Journal Article -
9
Levosimendan efficacy and safety : 20 Years of SIMDAX in clinical use
Published in Journal of cardiovascular pharmacology (01-07-2020)“…Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. Levosimendan was first approved for clinical use in 2000, when authorization was…”
Get full text
Journal Article -
10
NLRP3 Inflammasome in Acute Myocardial Infarction
Published in Journal of cardiovascular pharmacology (01-09-2019)“…Acute myocardial infarction (AMI) is associated with the induction of a sterile inflammatory response that leads to further injury. The NACHT, leucine-rich…”
Get full text
Journal Article -
11
PDSS2 Inhibits the Ferroptosis of Vascular Endothelial Cells in Atherosclerosis by Activating Nrf2
Published in Journal of cardiovascular pharmacology (29-04-2021)“…Cardiovascular disease ranks the leading cause of mortality worldwide. Prenyldiphosphate synthase subunits collectively participate in the formation and…”
Get full text
Journal Article -
12
A Novel Pharmacologic Inhibitor of the NLRP3 Inflammasome Limits Myocardial Injury After Ischemia–Reperfusion in the Mouse
Published in Journal of cardiovascular pharmacology (01-04-2014)“…BACKGROUND:The formation of the NLRP3 inflammasome in the heart during acute myocardial infarction amplifies the inflammatory response and mediates further…”
Get full text
Journal Article -
13
Low-dose Sinapic Acid Abates the Pyroptosis of Macrophages by Downregulation of lncRNA-MALAT1 in Rats With Diabetic Atherosclerosis
Published in Journal of cardiovascular pharmacology (01-02-2018)“…Pyroptosis is a type of programmed cell death, which has been associated with multiple inflammatory diseases including diabetic atherosclerosis (DA). This…”
Get full text
Journal Article -
14
Dapagliflozin Attenuates Contrast-induced Acute Kidney Injury by Regulating the HIF-1α/HE4/NF-κB Pathway
Published in Journal of cardiovascular pharmacology (01-06-2022)“…Contrast-induced acute kidney injury (CI-AKI) causes clinically acquired nephropathy in patients who undergo coronary interventions. Hypoxic injury to proximal…”
Get full text
Journal Article -
15
Panax Notoginseng Saponins Attenuate Myocardial Ischemia-Reperfusion Injury Through the HIF-1α/BNIP3 Pathway of Autophagy
Published in Journal of cardiovascular pharmacology (01-02-2019)“…BACKGROUND AND OBJECTIVE:Panax Notoginseng Saponins (PNS) is a formula of Chinese medicine commonly used for treating ischemia myocardial in China. However,…”
Get full text
Journal Article -
16
Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
Published in Journal of cardiovascular pharmacology (01-02-2022)“…Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented effects on reducing hospitalization for heart failure and cardiovascular mortality,…”
Get full text
Journal Article -
17
Energy Metabolic Phenotype of the Cardiomyocyte During Development, Differentiation, and Postnatal Maturation
Published in Journal of cardiovascular pharmacology (01-08-2010)“…Dramatic maturational changes occur in cardiac energy metabolism during cardiac development, differentiation, and postnatal growth. These changes in energy…”
Get full text
Journal Article -
18
Fibroblasts and Myofibroblasts: What Are We Talking About?
Published in Journal of cardiovascular pharmacology (01-04-2011)“…Cardiac myocytes, although large enough to make up most of the heart volume, are only a minority of cells within the heart with fibroblasts and blood vessel…”
Get full text
Journal Article -
19
Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19)
Published in Journal of cardiovascular pharmacology (01-05-2020)“…A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus…”
Get full text
Journal Article -
20
Inclisiran: A Novel Agent for Lowering Apolipoprotein B-Containing Lipoproteins
Published in Journal of cardiovascular pharmacology (01-08-2021)“…Hypercholesterolemia is a leading cause of cardiovascular morbidity and mortality. Accordingly, efforts to lower apolipoprotein B-containing lipoproteins in…”
Get full text
Journal Article